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Abstract 
The kinase Isr1 negatively regulates hexosamine biosynthesis in S. cerevisiae 
By Emma B. Alme 
 
Protein phosphorylation is an essential regulatory mechanism that controls most cellular 
processes, integrating a variety of environmental signals to drive cellular growth. Yeast 
encode over 100 kinases, yet many remain poorly characterized. The S. cerevisiae 
gene ISR1 encodes a putative kinase with no ascribed function. Here, we show that 
ISR1 decreases the synthesis of a critical structural carbohydrate, uridine diphosphate 
N-acetylglucosamine (UDP-GlcNAc), by mediating inhibition of one of the enzymes 
responsible for its synthesis, Gfa1. UDP-GlcNAc is the precursor to protein 
glycosylation, GPI anchor formation, and chitin synthesis, the first two of which are 
essential and conserved in humans. Throughout the cell cycle, and in response to 
changing environmental conditions, the cell must balance its use of glucose for energy 
production and generation of these structural carbohydrates. Here we show that Isr1 is 
regulated by both cell cycle and nutrient changes, and is rapidly degraded in a 
phosphorylation dependent manner. Isr1-mediated inhibition of UDP-GlcNAc synthesis 
may serve as a mechanism of dynamically regulating how the cell utilizes glucose in 
response to its environment. 
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Abstract 
The S. cerevisiae ISR1 gene encodes a putative kinase related to mammalian Raf and 
with no ascribed function. Here, we show that Isr1 acts as a negative regulator of the 
highly-conserved hexosamine biosynthesis pathway (HBP), which converts glucose 
into uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the carbohydrate 
precursor to protein glycosylation, GPI-anchor formation, and chitin biosynthesis. 
Overexpression of ISR1 is lethal and, at lower levels, causes sensitivity to tunicamycin 
and resistance to calcofluor white, implying impaired protein glycosylation and reduced 
chitin deposition. Gfa1 is the first enzyme in the HBP and is conserved from bacteria 
and yeast to humans. The lethality caused by Isr1 overexpression is rescued by co-
overexpression of GFA1 or exogenous glucosamine, which bypasses GFA1's essential 
function. Gfa1 is phosphorylated in an ISR1-dependent fashion and mutation of ISR1-
dependent sites ameliorates the lethality associated with Isr1 overexpression. Isr1 
contains a phosphodegron that is phosphorylated by Pho85 and 
subsequently ubiquitinated by the SCF-Cdc4 complex, largely confining Isr1 protein 
levels to the time of bud emergence. Mutation of this phosphodegron stabilizes Isr1 and 
recapitulates the overexpression phenotypes.  As Pho85 is a cell cycle and nutrient 
responsive kinase, this tight regulation of Isr1 may serve to dynamically regulate flux 
through the HBP and modulate how the cell’s energy resources are converted into 
structural carbohydrates in response to changing cellular needs.    
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Introduction 
 Protein phosphorylation is a major signaling mechanism that is critical to the 
control of most cellular processes [1–3]. It is estimated that 75% of the proteome is 
phosphorylated and kinases are among the largest protein families, comprising about 
2% of most eukaryotic genomes [4]. Kinases often act in   cascades to amplify signals 
and there is significant cross-talk amongst protein kinases, allowing for the coordination 
of many cellular inputs. Despite their abundance and critical regulatory roles in the cell, 
many of the approximately 130 yeast kinases remain poorly characterized [5]. 
One such kinase is Inhibitor of Staurosporine Resistance 1 (Isr1), which is 
annotated as a putative kinase based on homology of its kinase domain to Raf [6]. Raf 
kinase is a MAPKK best known for its oncogenic functions downstream of RAS in 
humans [7]. In S. cerevisiae, no Raf homologue has been identified and RAS functions 
primarily upstream of adenylyl cyclase in response to nutrient levels [8]. The Isr1 kinase 
domain shares 24% identity and 43% similarity to Byr2, the Raf homologue in S. 
pombe. However, while Byr2 binds to and is directly activated by RAS, Isr1 does not 
appear to be downstream of RAS [9,10]. 
ISR1 was first identified as a gene whose deletion is synthetic lethal with a 
temperature-sensitive allele of PKC1 and whose overexpression sensitized cells to 
staurosporine, a Pkc1 inhibitor [6]. While the molecular basis for these phenotypes was 
unknown, they suggested a defect in cell wall homeostasis. Pkc1 is essential to the cell 
wall integrity pathway, which is critical to remodeling the cell wall in response to cellular 
growth and environmental stress [11].  Other studies identified ISR1 as a gene whose 
overexpression causes sensitivity to caffeine, a general cell wall stress agent, and 
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resistance to zymocin [12]. As chitin is the cellular receptor for zymocin [13], these 
phenotypes are consistent with reduced levels of chitin, a minor but critical structural 
component of the cell wall, comprising approximately 2% of the cell wall by mass [14]. 
The major protein component of the cell wall is glycosylphosphatidylinositol (GPI) 
anchors. Both GPI anchors and chitin share the same carbohydrate precursor, uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc), which is also the precursor for protein 
glycosylation [14]. Many proteins involved in cell wall carbohydrate biosynthesis are 
heavily glycosylated, making regulated production of this carbohydrate essential for 
proper cell wall homeostasis. N-glycosylation is also critical to many other cellular 
processes, including proper protein folding and trafficking as well as cell cycle 
progression [14,15]. The cellular requirement for UDP-GlcNAc changes throughout the 
cell cycle. While protein glycosylation occurs continuously as a cell grows, chitin 
synthesis predominates in G1 at the time of bud emergence and chitin deposition also 
greatly increases in response to cell wall stress [16–20].  
UDP-GlcNAc is synthesized via the hexosamine biosynthesis pathway (HBP), 
which is highly conserved from bacteria to humans [21]. Most of the glucose imported 
into the cell is shunted into glycolysis after it is converted to fructose-6-phosphate, but 
approximately 6% enters the hexosamine biosynthesis pathway where it is converted 
into UDP-GlcNAc though the sequential action of four enzymes: glutamine: fructose-6-
phosphate aminotransferase (Gfa1), GlcN-6-P acetyltransferase (Gna1), 
Phosphoacetyl-glucosamine mutase (Pcm1) and UDP-GlcNAc pyrophosphorylase 
(Qri1) [22]. The first step of this pathway, conversion of fructose-6-phosphate and 
glutamine to glucosamine-6-phosphate, is mediated by Gfa1 and is the rate limiting step 
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of the pathway [17,21]. Gfa1 activity has been shown to be directly proportional to UDP-
GlcNAc synthesis and is regulated by nutrient and stress-responsive kinases (23–27). 
We have identified a role for Isr1 as an inhibitor of the HBP, establishing a 
function for this kinase. High levels of Isr1 promotes Gfa1 phosphorylation, and 
inhibition of the HBP by Isr1 is relieved by mutation of these Gfa1 phosphosites or 
bypassing Gfa1 by exogenous addition of glucosamine. Additionally, we have identified 
a critical Pho85-regulated SCFCDC4 phosphodegron in ISR1. Mutation of this 
phosphodegron strongly affects HBP activity, highlighting how strict control of this 
kinase by post-translational modification can allow for signal integration and tight 
regulation of the HBP in response to changing cellular stimuli.   
  7 
Results 
Overexpression of Isr1 kinase activity is lethal 
To begin to understand the role Isr1 might play in the cell, we first sought to test 
the effect of overexpressing ISR1. We placed the ISR1 ORF under the control of the 
GAL1 promoter on a 2µ plasmid. At this level of expression (referred to as GAL-2µ), Isr1 
is lethal to the cell (Fig 1.1.1A). Isr1 is a putative kinase and mutation of the predicted 
aspartic acid proton acceptor in its kinase domain to alanine abolished this lethality, 
indicating that kinase activity is required for Isr1 function (Fig 1.1A). Isr1 is a very low 
abundant protein [28] and difficult to overexpress for reasons that are currently 
unknown. The expression level of Isr1 from a 2µ plasmid utilizing the ISR1 promoter 
(referred to as 2µ ISR1) is low compared to GAL-2µ ISR1, and even GAL-2µ ISR1 does 
not result in extremely high levels of Isr1 (Fig 1.1B). To determine the levels of Isr1 
achieved by this construct, we epitope tagged Pkc1 expressed under its endogenous 
promoter using a 3x-Flag tag, the same epitope tag used for Isr1. Based on comparison 
of these proteins by western blot, GAL-2µ Isr1 protein levels are similar to the 
endogenous expression level of Pkc1 (Fig 1.1C).  
 
Isr1 does not function in RNA processing 
In contrast to the lethality we saw with GAL-2µ ISR1, in large scale studies using 
the MATa deletion collection, deletion of ISR1 has resulted in few phenotypes [29]. 
ISR1 deletion was shown to result in sensitivity to cordycepin, an adenosine analogue 
that causes premature termination, indicating a role in RNA processing [30]. However, 
we found that while the isr1∆::KanMX strain isolated from the MATa deletion collection 
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did show sensitivity to cordycepin (Fig 1.2A), this was not rescued by integrating ISR1 
at the endogenous locus in this strain. By contrast, we observed that isr1∆ was resistant 
to tunicamycin, an N-glycosylation inhibitor [31]. This phenotype was not previously 
reported and sensitivity to tunicamycin was restored by integrating ISR1 in the isr1∆ 
strain (Fig 1.2A). This indicates that tunicamycin resistance, but not cordycepin 
sensitivity, is dependent on Isr1 activity.  The 3’UTR of ISR1 overlaps with that of its 
neighboring gene, YTH1, which is an essential component of the mRNA cleavage and 
polyadenylation factor. Thus, the cordycepin sensitivity of the isr1∆ strain from the 
deletion collection is likely a result of a reduction in function of YTH1. Importantly, many 
of the genetic interactions reported for ISR1 from large scale studies using the MATa 
deletion collection are likely due to this neighboring gene effect as well, making it 
difficult to discern which phenotypes are specific to ISR1. This caveat of large scale 
collections has been previously described and the neighboring gene effect is estimated 
to result in incorrect annotation of approximately 10% of genes [32]. We generated our 
own isr1∆ strain using a hygromycin selectable marker and found that this strain did not 
exhibit sensitivity to cordycepin, but did show resistance to tunicamycin (Fig 1.2A). This 
isr1∆::HygMX strain is used in all subsequent experiments. 
 
Isr1 overexpression has phenotypes associated with a deficiency in UDP-GlcNAc  
Given the resistance to tunicamycin that we uncovered with our newly generated isr1∆ 
strain, we wished to determine if higher levels of ISR1, reciprocally, caused tunicamycin 
sensitivity.  Because of the lethality associated with GAL-2µ ISR1, we performed this 
characterization utilizing 2µ ISR1. We added a NAT selectable marker to the plasmid to 
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allow drug screening on rich media containing NAT instead of synthetic dropout media, 
allowing for lower concentrations of drugs to be used. 2µ overexpression of ISR1, but 
not a kinase dead allele, isr1-D280A, resulted in sensitivity to tunicamycin (Fig 1.2B). 
Tunicamycin acts as an ER-stress agent by inhibiting the first step in N-glycosylation, 
which involves the transfer of N-acetylglucosamine-1-phosphate (GlcNAc-1-P) from 
UDP-N-acetylglucosamine (UDP-GlcNAc) to the carrier lipid dolichyl-phosphate (Dol-P) 
[31,33].  Thus, the sensitivity to tunicamycin in response to Isr1 overexpression could be 
due to a defect in N-glycosylation or a general increase in ER-stress. To distinguish 
between these possibilities, we tested if ISR1 overexpression conferred sensitivity to 
other ER stress agents and found that GAL-2µ ISR1 did not confer sensitivity to DTT, 
suggesting that the tunicamycin sensitivity is not due to a general increase in ER-stress 
(Fig 1.2C). For reasons that are currently unknown, the GAL-2µ ISR1 phenotype is less 
severe on synthetic media, allowing this sensitivity test to be performed.  
We also found that 2µ ISR1 conferred resistance to calcofluor white (Fig 1.2B), 
recapitulating previous data indicating a role for ISR1 in cell wall integrity [12]. 
Calcofluor white is a cell-wall stress agent that targets chitin and resistance indicates a 
specific deficiency in chitin deposition in the cell wall. Deletion of the main chitin 
synthase, Chs3, results in complete resistance to calcofluor white, whereas other cell 
wall mutants or overproduction of chitin results in sensitivity [13,34–36].  
Both chitin and protein glycosylation are produced from the same precursor 
carbohydrate, UDP-GlcNAc, which is also the precursor for GPI anchors (Fig 1.2D). 
Chitin and GPI anchors predominantly function at the cell surface: GPI anchors are the 
major protein component of the cell wall, whereas chitin is a more minor, but still critical 
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structural component [14,18]. N-glycosylation functions on the cell surface as well, but is 
also essential for proper protein folding and trafficking [15]. Previous studies have 
shown that blocking GPI anchor formation increases chitin deposition in the cell wall 
[37]. UDP-GlcNAc synthesis is the rate-limiting step in the production of chitin, which is 
a polymer of UDP-GlcNAc, and GPI-anchor inhibition is thought to allow the 
accumulation of excess UDP-GlcNAc that is no longer converted into GPI anchors 
[17,37].  
The tunicamycin sensitivity of the 2µ ISR1 strain and the tunicamycin resistance 
observed in the isr1∆ strain might be due to misregulation of protein N-glycosylation. If 
ISR1 overexpression specifically inhibited N-glycosylation, one would expect a larger 
pool of available UDP-GlcNAc for chitin synthesis, resulting in a compensatory increase 
in chitin production. However, we observed that 2µ ISR1 caused resistance to calcofluor 
white, indicating a deficiency in chitin deposition. This is consistent with a defect in both 
protein glycosylation and chitin biosynthesis. This suggest that Isr1 acts upstream of N-
glycosylation, reducing UDP-GlcNAc production. 
 
Isr1 overexpression is synthetic lethal with enzymes in the hexosamine 
biosynthesis pathway  
 Most of the glucose imported into the cell is shunted into glycolysis after it is 
converted to fructose-6-phosphate, but approximately 6% enters the hexosamine 
biosynthesis pathway (HBP), where fructose-6-phosphate and glutamine are converted 
into UDP-GlcNAc though the sequential action of four enzymes: Gfa1, Gna1, Pcm1, and 
Qri1 (Fig 1.2D) [22]. This pathway is highly conserved from bacteria to humans [21]. 
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Given that each of these enzymes are essential, we generated heterozygote deletions 
in genes encoding each of these enzymes and expressed GAL1-ISR1 in these strains 
to test the genetic interactions of this pathway with ISR1. We found that GAL-2µ ISR1 is 
synthetic lethal with all four enzymes in the pathway (Fig 1.2E). Notably, diploid wildtype 
cells are less sensitive to GAL-2µ ISR1 as compared to haploid cells. Gln1 is not part of 
the HBP, but synthesizes glutamine, one of the precursors to the pathway [38], and also 
exhibits synthetic sickness in combination with GAL-2µ ISR1. These genetic interactions 
suggest that ISR1 overexpression inhibits the HBP. 
 
Isr1 lethality is rescued by exogenous glucosamine, but not other precursors to 
UDP-GlcNAc synthesis 
 The first enzyme of this pathway, Gfa1, converts fructose-6-phosphate and 
glutamine to glucosamine-6-phosphate (Fig 1.3A) [39]. This is the rate-limiting step of 
the pathway and Gfa1 activity is proportional to chitin synthesis [17]. GFA1 essentiality 
can be by-passed by exogenous glucosamine, which can be phosphorylated by 
hexokinases. Thus, gfa1∆ strains are glucosamine auxotrophs. Addition of exogenous 
glucosamine drives flux through the HBP and increases UDP-GlcNAc production 
[39,40]. We tested if the lethality associated with GAL-2µ ISR1 overexpression can be 
rescued by addition of exogenous glucosamine and found that in the presence of 5mM 
glucosamine, GAL-2µ ISR1 no longer inhibited growth (Fig 1.3B). Some cell wall 
mutants have growth phenotypes that can be rescued by both exogenous glucosamine 
and by addition of sorbitol to the media [40]. As sorbitol is an osmotic stabilizer, this 
implies that the slow growth phenotype of such mutants is caused by cell lysis due to a 
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weakened cell wall. To determine if a similar general cell wall defect is responsible for 
the lethality associated with GAL-2µ ISR1, we tested growth of this strain in the 
presence of 10% sorbitol and found that sorbitol was not capable of rescuing growth 
(Fig 1.S1). This suggests that the lethality of GAL-2µ ISR1 is due to a growth arrest 
caused by a deficiency of UDP-GlcNAc production and not cell lysis caused by a 
weakened cell wall.  
 As expected, addition of glucosamine also restored sensitivity of the 2µ ISR1 
overexpression strain to calcofluor white by driving flux through the HBP and increasing 
the amount of UDP-GlcNAc (Fig 1.3C). By contrast, glucosamine did not restore 
sensitivity to chs3∆ (Fig 1.3C), as an increase in UDP-GlcNAc cannot restore chitin 
synthesis in the absence of the chitin synthase itself. Thus, the resistance to calcofluor 
white observed upon 2µ overexpression of ISR1 is unlikely to be due to a general 
trafficking defect that mislocalizes Chs3.  This is in agreement with the lack of sensitivity 
observed upon exposure to DTT. Similarly, exogenous glucosamine restored growth to 
the 2µ ISR1 strain in the presence of tunicamycin (Fig 1.3C). The ability of glucosamine 
to rescue ISR1 overexpression phenotypes implies that Isr1 acts at or before the first 
step of the HBP. To determine if a deficiency in one of the precursors to the HBP is 
responsible for the ISR1 overexpression phenotypes, we tested if fructose and 
glutamine, the reactants in the production of glucosamine-6-phosphate (Fig 1.3A), could 
rescue the ISR1 overexpression phenotypes. We also tested alternative or non-
fermentable carbon sources, which by-pass glycolysis entirely, and found that neither 
the precursors to the HBP nor non-fermentable carbon sources were capable of 
rescuing ISR1 overexpression phenotypes (Figs 3C and 3D, Fig 1.S1). The ability of 
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glucosamine, but not precursors to the HBP, to completely rescue ISR1 overexpression 
phenotypes indicates that Isr1 likely inhibits the first step of the HBP.  
 
Isr1 is a negative regulator of GFA1 
Our observation that exogenous glucosamine rescues the lethality associated 
with GAL-2µ ISR1 overexpression suggests that Isr1 might inhibit flux through the HBP. 
If this is the case, overexpression of GFA1 should rescue this lethality as well. To 
explore this possibility, we co-overexpressed GFA1 on the same plasmid as GAL1-ISR1 
and as expected, GFA1 overexpression also rescued the lethality associated with GAL-
2µ ISR1 overexpression (Fig 1.4A). To determine if this was unique to GFA1, we co-
overexpressed another enzyme downstream in this pathway, Qri1, with GAL1-ISR1. 
QRI1 only mildly increased growth on galactose, suggesting that Isr1 acts at the level of 
Gfa1 within the HBP (Fig 1.4A).  
In other organisms, including C. albicans, drosophila, and humans, 
phosphorylation by multiple kinases, including AMPK and PKA, has been shown to both 
positively and negatively regulate Gfa1 activity [23–26,41,42]. Overexpression of ISR1 
did not alter Gfa1 protein levels (Fig 1.S2), suggesting that it might act by inhibiting Gfa1 
function. However, the GFA1-TAP allele was unable to support viability and therefore it 
remains possible that the epitope tagged GFA1 allele is stabilized or cannot be targeted 
by Isr1. 
A previous mass spectrometry study of kinase interactors identified Gfa1 as a 
physical interactor with Isr1 in three separate immunoprecipitation experiments [43]. 
Given this, we sought to determine if Gfa1 is phosphorylated in an Isr1-dependent 
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manner.  We conducted phosphoproteomics in isr1∆ cells expressing either an empty 
vector or GAL-2µ ISR1 and detected over 8,779 
distinct phosphorylated peptides on 1,860 proteins. In this experiment, we detected 4 
sites of phosphorylation on Gfa1: S199, S253, S332, and T334.  Of these sites, the 
doubly phosphorylated peptide containing S332 and T334 was 12.9-fold up-regulated in 
ISR1-expressing cells (Fig 1.4B).  Additionally, a singly phosphorylated S332 peptide 
was also observed only in the ISR1-expressing cells.  Targeted data extraction for this 
peptide revealed its phosphorylation level was 179-fold higher in ISR1-expressing cells 
(Fig 1.4C). To examine the importance of these phosphorylations, we mutated S332, 
T334, and S336 to alanine. S336 was included because it was adjacent to the other two 
sites and was seen to be phosphorylated in a previous whole-phosphoproteome screen 
[44]. Mutation of S332, T334, and S336 to alanine at the endogenous locus (referred to 
as GFA1-3A) rescued the lethality associated with GAL-2µ ISR1 overexpression (Fig 
1.4D). This suggests that Isr1 inhibits Gfa1 by promoting its phosphorylation. 
 Notably, the GFA1-3A mutant was slightly hypomorphic. While the GFA1-3A 
strain had no growth defect under normal conditions, it was sensitive to tunicamycin and 
resistant to calcofluor white (Fig 1.4E, S2C).  This sensitivity was recessive, as 
expected for a hypomorph, and was epistatic to 2µ ISR1 (Fig 1.4D, Fig 1.S2). By 
contrast, the GFA1-3A mutant was also dominant in its ability to rescue GAL-2µ ISR1 -
induced lethality: the GFA1/GFA1-3A heterozygous diploid was resistant to GAL-2µ 
ISR1 (Fig 1.4F). Our finding that the resistance conferred by GFA1-3A is dominant is 
consistent with the hypothesis that GFA1-3A rescues ISR1 overexpression because it is 
refractory to inhibition by Isr1. These data suggest Isr1 is a negative regulator of Gfa1. 
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 It should be noted that, while the GFA1 phosphomutant rescued GAL-2µ ISR1 -
induced lethality, GFA1-3A cells overexpressing ISR1 still grew more slowly than GFA1-
3A cells overexpressing isr1-D280A. Therefore, while our data support a model where 
Isr1 inhibits the HBP by promoting the phosphorylation of Gfa1, Isr1 may have 
additional substrates, additional sites on Gfa1, or both.  
 
Isr1 is an unstable cell-cycle regulated protein targeted by Pho85 and Cdc4 
 Given that even mild overexpression of Isr1 inhibits the essential function of 
Gfa1, we next sought to understand how Isr1 is regulated in the cell. The cellular need 
for UDP-GlcNAc varies throughout the cell cycle and we therefore tested if Isr1 is a cell 
cycle regulated protein. Analysis of Isr1 protein levels after arresting cells in each phase 
of the cell cycle showed that Isr1 protein levels are largely confined to the G1/S 
transition and are drastically reduced in G1 and M phases (Fig 1.5A). This matches 
known transcriptional data for ISR1 [45]. Previous work from our lab suggested that Isr1 
is a substrate of Cdc4 [46]. Cdc4 is an F box protein that functions as a substrate 
adaptor for the SCF ubiquitin ligase complex and targets many substrates for 
proteasome-mediate degradation in a cell-cycle dependent manner [47]. Consistent with 
this, a cycloheximide chase of Isr1-13xMyc in wildtype cells, as compared to 
temperature-sensitive mutants of CDC4 and CDC53, showed that Isr1 is unstable, with 
a half-life of approximately 30 minutes, and is stabilized by inactivation of CDC4 or 
CDC53 (Fig 1.5B).  
Cdc4 recognizes and binds a phosphodegron with the optimal sequence (S/T)-P-
X2-4 –(S/T) in which both (S/T) are phosphorylated, often by CDK kinases [48–51]. Isr1 
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was previously identified as an in vitro substrate of Pho85 [52], a CDK-like kinase that 
can function with any of 10 different cyclins in response to changes in nutrient and cell-
cycle conditions [53,54]. Isr1 was shown to be phosphorylated by Pho85 in complex 
with Pcl1, which functions in G1 progression [52,55]. We found that deletion of PHO85 
stabilized Isr1, suggesting that Pho85-phosphorylation of Isr1 enables Isr1 to be 
targeted by Cdc4 for degradation (Fig 1.5C). Deletion of PCL1 also partially stabilized 
Isr1 (Fig 1.5D). Given this partial stabilization, it remains possible that other Pcls, in 
addition to Pcl1, can also function with Pho85 to target Isr1. Pho85 is inhibited by the 
CDK inhibitor Pho81 in low phosphate conditions [56]. Upon release into low phosphate 
media, Isr1 levels increased, as would be expected if Pho85 activity promotes its 
instability (Fig 1.5E). Pho85 activity has also been shown to regulate carbohydrate 
metabolism [53,57]. We therefore tested if Isr1 stability was altered by carbon source. 
We found that growth in glycerol, a non-fermentable carbon source, as well as glucose 
withdrawal, also partially stabilized Isr1, whereas growth in galactose did not (Fig 1.S3). 
This supports a model where Pho85-mediated degradation of Isr1 might allow Isr1 
activity to be responsive to environmental conditions.  
 
Stabilization of an endogenous Isr1 phosphodegron recapitulates Isr1 
overexpression phenotypes 
 Examination of the Isr1 protein sequence revealed two putative Cdc4 
phosphodegrons in the N-terminus of the protein, each comprising two CDK consensus 
phosphorylation sites separated by several amino acids (Fig 1.6A). We constructed an 
ISR1 phosphodegron mutant (ISR1-PD) by mutating these four residues (T4, S8, T86, 
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S92) as well as two adjacent serine/threonine residues to alanine at the endogenous 
locus. The ISR1-PD mutant was completely stable (Fig 1.6B), strongly supporting a 
model where phosphorylation of Isr1 at these sites targets it for degradation by Cdc4.  
We next tested if this regulation is functionally relevant by examining the 
calcofluor white sensitivity of the ISR1-PD mutant. We found that these mutations are 
sufficient to cause resistance to calcofluor white, consistent with there being higher 
levels of Isr1 activity in ISR1-PD mutants (Fig 1.6C). This same resistance was 
recapitulated on Congo Red, a cell-wall stress agent that also targets chitin (Fig 1.S4) 
[58]. Similarly, the ISR1-PD mutant was also highly sensitive to tunicamycin (Fig 1.6D). 
Taken together, these data show that the endogenous phosphodegron mutant of Isr1 
recapitulates ISR1 overexpression phenotypes, supporting a model where tight 
regulation of Isr1 is critical for controlling its function in the cell. Interestingly, deletion of 
the entire N-terminal 93 amino acids of Isr1, which includes both phosphodegrons, was 
also sensitive to tunicamycin (Fig 1.6D). This implies that this truncation mutant is active 
and the only function of the N-terminus of Isr1 is in mediating its instability. Our mass 
spectrometry data also identified an additional proline-directed phosphorylation site in 
Isr1, S47, that may also be targeted by Pho85 or could represent autophosphorylation. 
 To determine the physiological relevance of Isr1 regulation, we tested the genetic 
interactions of this Isr1 phosphodegron mutant with deletions of the enzymes of the 
HBP pathway. Because these genes are essential, we examined diploids that were 
heterozygous for each HBP gene, as well as the ISR1-PD mutant. We found that 
ISR1/ISR1-PD showed a level of sensitivity to tunicamycin similar to that seen for 
GFA1/gfa1∆ (Fig 1.6E). One interpretation of this is that one copy of the stabilized Isr1 
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phosphodegron mutant reduces Gfa1 activity by half. Notably, The GFA1/gfa1∆ strain 
grew more slowly on tunicamycin than deletions of the other three enzymes in the 
pathway, as would be expected given that Gfa1 is the rate-limiting step of the pathway. 
While ISR1/ISR1-PD and GFA1/gfa1∆ were virtually synthetic lethal in the presence of 
tunicamycin, this synthetic sickness was not observed when ISR1-PD was combined 
with other deletions in the pathway. The specificity of this synthetic interaction further 
supports a model where Isr1 activity negatively regulates Gfa1 function and emphasizes 
the large effect of an even minor increase in Isr1 stabilization on flux through the HBP.  
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Discussion 
Throughout the cell cycle and in response to changing nutrient conditions, the 
cell must balance its utilization of glucose for energy needs and as a precursor to 
structural and signaling carbohydrates. Here, we uncover a function for a previously 
uncharacterized kinase, Isr1, as a negative regulator of the hexosamine biosynthesis 
pathway (HBP) that synthesizes UDP-GlcNAc from glucose.  
Isr1 previously had no ascribed function and its designation as a kinase was 
predicted based on homology to Raf [6]. Only ~15% of yeast genes are phenotypic 
when overexpressed [59]. The lethality of overexpressing ISR1, combined with the 
limited phenotypes of its deletion, support a model where Isr1 is a negative regulator of 
an essential protein. Our data firmly establishes a role for Isr1 in inhibition of the HBP 
based on several lines of evidence. First, 2µ overexpression of Isr1 results in resistance 
to calcofluor white and sensitivity to tunicamycin, whereas isr1∆ is slightly sensitive to 
calcofluor white and resistant to tunicamycin. These opposing phenotypes are 
consistent with a deficiency in UDP-GlcNAc when Isr1 is overexpressed and an 
increase in UDP-GlcNAc when Isr1 is absent. Genes that function in protein trafficking 
or the downstream utilization of UDP-GlcNAc in protein glycosylation are expected to 
have a compensatory increase in chitin production and to have a sensitivity to other ER-
stress agents [37]. This was not observed for ISR1 overexpression, suggesting that it 
inhibits the HBP itself. Consistent with this, we found that ISR1 overexpression is 
synthetic lethal with every enzyme in the HBP.   
All phenotypes of Isr1 overexpression are rescued by either overexpressing 
GFA1, the enzyme of the first step of the HBP, or by bypassing GFA1 function by the 
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addition of exogenous glucosamine. Addition of reactants upstream of Gfa1, such as 
fructose and glutamine, had no effect. This strongly suggested that Isr1 inhibits this first 
step in the HBP. Furthermore, we found that phosphorylation of a specific serine in Gfa1 
is dependent on Isr1 activity and mutation of this phosphorylation site to alanine 
rendered cells insensitive to ISR1 overexpression. Thus, Isr1 appears to act as a 
negative regulator of Gfa1. The GFA1 phosphomutant is hypomorphic, yet epistatic to 
ISR1 overexpression and dominant in its ability to rescue GAL-2µ ISR1 lethality, 
strongly implying that Isr1 exerts its function in the cell by promoting Gfa1 
phosphorylation.  
Isr1 may phosphorylate Gfa1 directly, as suggested by the existing 
immunoprecipitation -mass spectrometry data, or it might act in a kinase cascade. 
However, our phosphoproteomics dataset did not reveal specific activation of other 
kinases that might act downstream of Isr1. Notably, deletion of the majority of the N-
terminal domain of Isr1 rendered Isr1 more active, implying that this portion of the 
protein is not required for substrate specificity. Given that the remaining residues 
comprise little more than a kinase domain, it remains unclear how Isr1 targets its 
substrates. 
Additional genetic evidence suggests an interaction between ISR1 and GFA1: 
Isr1 was identified due to the fact that its overexpression resulted in heightened 
sensitivity to staurosporine, an inhibitor of Pkc1 and ISR1 deletion is synthetic lethal 
with a temperature sensitive allele of PKC1 [6]. Pkc1 is known to positively regulate 
GFA1 transcription through Rlm1 activation [27,60]. Therefore, this synthetic lethality is 
consistent with a role for Isr1 as a negative regulator of Gfa1. Similarly, ISR1 has been 
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reported in multiple studies to have strong negative genetic interaction with PRR1 
[3,61,62], a kinase that is a physical interactor with Gfa1 [43]. These data would be 
consistent with Prr1 and Isr1 independently regulating Gfa1. Notably, prr1∆ does not 
rescue GAL-2µ ISR1 lethality (Fig 1.S5).  
The human homologue of Gfa1, Gfat1, has been previously shown to be 
negatively regulated by phosphorylation via AMPK and PKA [23,24,41]. Thus, inhibition 
of Gfa1 via phosphorylation may be a convergent or conserved mechanism of 
regulating hexosamine biosynthesis in response to changes in nutrients. The closest 
homologue of Isr1 in S. pombe is Byr2, which is a homologue of mammalian Raf and 
directly downstream of Ras [9]. While Isr1 is not thought to interact with Ras in S. 
cerevisiae, Ras2 has been shown to function downstream of the hexosamine 
biosynthesis pathway as a negative regulator of GPI anchor formation [37]. Ras2 
inhibition of GPI anchor formation has been posited to allow remodeling of cell wall 
architecture in response to environmental stimuli by decreasing GPI-anchored proteins 
at the cell wall and, as a result of the increase in available UDP-GlcNAc, increasing 
chitin biosynthesis [37]. Thus, while Isr1 has diverged from the RAS/cAMP signaling 
pathway, it appears that both Isr1 and RAS work to integrate environmental signals to 
regulate the remodeling of the cell wall and glycoprotein biosynthesis. 
 The cellular requirement for UDP-GlcNAc changes throughout the cell cycle.  
While protein glycosylation occurs continuously as a cell grows, chitin synthesis 
predominates in G1 at the time of bud emergence [16]. Indeed, Gfa1 expression 
increases during G1 or in response to pheromone or cell wall stress  [27,37,45]. Thus, 
dynamic control of Gfa1 is required to properly shunt glucose into or away from the 
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hexosamine biosynthesis pathway as needed. Notably, Isr1 protein levels peak at the 
G1/S transition, just after the period of time during the cell cycle at which higher levels 
of chitin synthesis are required. Given that Gfa1 activity is directly proportional to chitin 
synthesis [17], Isr1 might provide a mechanism of rapidly returning the cell to a normal 
level of chitin synthesis following bud emergence. Gfa1 is a highly abundant protein, 
whereas Isr1 is expressed at very low levels. We speculate that tight regulation of Isr1 
protein levels via Pho85 and Cdc4 might allow for rapid dynamic changes in Gfa1 
activity and could provide the cell with a less energetically costly mechanism of 
regulating Gfa1 function than degrading Gfa1 itself. While more studies are required to 
determine the specific environmental inputs that modulate Isr1 instability and the 
mechanism by which Isr1 inhibits Gfa1, this work firmly establish a cellular function for 
Isr1 as a key negative regulator of an essential, conserved pathway.   
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Fig 1.1. Overexpression of Isr1 is lethal.  
(A) Wild type cells were transformed with an empty vector (EV) or 2µ plasmid 
expressing either a wildtype (GAL-2µ ISR1) or a kinase-dead allele of ISR1 (GAL-2µ 
isr1-D280A) from the GAL1 promoter. Cells were serially diluted on YPD or YPGal 
plates. (B) Western blot showing relative expression level of Isr1-3xFlag expressed on a 
2µ plasmid from either its endogenous promotor (2µ ISR1) or the GAL1 promoter (GAL-
2µ). Cells were inoculated into YM-1 with the indicated carbon source and grown for 4 
hours under NAT selection. (C) Relative levels of Isr1-3xFlag expressed from the GAL1 
promoter compared to Pkc1-3xFlag tagged at the endogenous locus. 
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Fig 1.2.  Altering ISR1 dosage confers phenotypes associated with changes in 
flux through the hexosamine biosynthesis pathway. 
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(A) isr1∆::KanMX, isolated from the Mat a deletion collection, exhibits a sensitivity to 
cordycepin that is not shared by isr1∆::HygMX generated in this study. Both exhibit 
resistance to tunicamycin. Strains of the indicated genotypes were grown on YPD alone 
or containing 40 µg/ml cordycepin or 0.5 µg/ml tunicamycin. (B) 2µ ISR1 causes 
sensitivity to tunicamycin and resistance to calcofluor white (CFW). Strains of the 
indicated genotypes were transformed with EV, or a 2µ plasmid expressing either a 
wildtype (2µ ISR1) or a kinase-dead allele of ISR1 (2µ isr1-D280A) from the ISR1 
promoter. Strains were spotted on CSM in the presence or absence of 0.25 µg/ml 
tunicamycin or 30 µg/ml CFW. (C) Overexpression of Isr1 does not cause sensitivity to 
DTT. Wildtype cells were transformed with GAL-2µ ISR1 or GAL-2µ isr1-D280A and 
spotted as in B on CSM-URA plates containing glucose, galactose or galactose + 1 mM 
DTT. (D) The hexosamine biosynthesis pathway converts fructose-6-phosphate and 
glutamine into UDP-GlcNAC, the precursor to N-glycosylation, GPI-anchors, and chitin. 
Gln1 acts upstream of the HBP and is required for glutamine synthesis. (E) GAL-2µ 
ISR1 is synthetic lethal with all the enzymes in the HBP. Diploid heterozygous deletions 
of the enzymes in the HBP were generated and transformed with GAL-2µ ISR1 and 
struck on YPD or YPGal plates. Note that wildtype diploids are less sensitive than 
haploid strains to Isr1 overexpression.  
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Fig 1.3: Exogenous glucosamine specifically rescues Isr1 overexpression 
phenotypes. 
(A) Gfa1, the first and rate limiting enzyme in the HBP, converts fructose-6-phosphate 
and glutamine into glucosamine-6-phosphate. GFA1 essentiality can be bypassed by 
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addition of exogenous glucosamine. (B) Exogenous glucosamine rescues GAL-2µ ISR1 
lethality. Wildtype cells were transformed with GAL-2µ ISR1 or GAL-2µ isr1-D280A and 
spotted onto CSM + 5mM glucosamine, CSM galactose, or CSM galactose + 5mM 
glucosamine. (C) Exogenous glucosamine, but not fructose, restores resistance to 
tunicamycin and sensitivity to CFW. Strains of the indicated genotypes were 
transformed EV, 2µ ISR1, or 2µ isr1-D280A. Strains were spotted on CSM alone or 
containing 0.25 µg/ml tunicamycin, 30 µg/ml CFW, 5 mM glucosamine, or 2% fructose 
as indicated. (D) Lethality of GAL-2µ ISR1 is not rescued by precursors to the HBP. 
Experiment was performed as in B and strains were spotted on CSM alone or CSM + 
galactose containing 5 mM glutamine or glutamate (MSG).  
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Fig 1.4. Gfa1 is phosphorylated in an Isr1-dependent manner and a GFA1 
phosphomutant rescues Isr1 lethality.  
(A) GFA1 overexpression rescues the lethality of GAL-2µ ISR1. Wildtype cells were 
transformed with a 2µ plasmid expressing either ISR1 or isr1-D280A from the GAL1 
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promoter and either GFA1 or QRI1 from their endogenous promoters. Cells were serial 
diluted onto YPD or YPGal. (B) The Gfa1 S332 S334 phosphopeptide is enriched in 
cells expressing GAL-2µ ISR1. Volcano plot of phosphopeptides detected in isr1∆ cells 
expressing EV or GAL-2µ ISR1.  Peptides with a p < 0.01 and having a fold change +/- 
4-fold different between are considered significant. (C) Gfa1 S332 is phosphorylated in 
an Isr1-dependent manner. Targeted data extraction for Gfa1 S332 phosphorylation 
sites, which was only detected in the Gal-2u ISR1 conditions.  P-value is the result of 
a two-sided unpaired t-test. (D) Mutation of GFA1 phosphorylation sites at the 
endogenous locus ameliorates the lethality of GAL-2µ ISR1. Wildtype cells or a GFA1 
phosphomutant (S332A,T334A, S336A) were transformed with EV or GAL-2µ ISR1 and 
spotted as in A. (E) The GFA1-3A allele is hypomorphic. Cells of the indicated 
genotypes were transformed with EV or 2µ ISR1 and serial diluted on YPD in the 
presence or absence of 0.1 µg/ml tunicamycin. (F) Experiment was performed as in D 
with diploid cells of the indicated genotypes.  
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Fig 1.5.  Isr1 is an unstable protein targeted by Pho85 and Cdc4. 
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(A) Isr1 is cell cycle regulated. Western blot showing levels of Isr1-13xmyc in cells 
growing asynchronously or arrested in G1, S, or M phase with alpha factor, 
Hydroxyurea (HU) or nocodazole, respectively. PSTAIR and Pds1 are shown as loading 
and cell cycle arrest controls, respectively. (B) Isr1 is targeted for degradation by Cdc4. 
Cycloheximide-chase assay of Isr1-13xmyc in wildtype, cdc4-1, or cdc53-1 strains. 
Cells were shifted to the non-permissive temperature for 30 minutes before addition of 
cycloheximide for the indicated number of minutes. Levels of Isr1-13xMyc and PSTAIR 
(loading control) are shown. (C) Degradation of Isr1 is dependent on Pho85. Experiment 
was performed as in B at 30°C in PHO85 or pho85∆ cells. Rad53 is shown as a loading 
control (D) Isr1 is stabilized by deletion of PCL1. Experiment as in B at 30°C in PCL1 or 
pcl1∆ cells. (E) Western blot showing levels of Isr1-13xMyc and PSTAIR (loading 
control) after shifting cells to low phosphate media for 60 minutes.  
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Fig 1.6. Stabilization of an endogenous Isr1 phosphodegron recapitulates 
overexpression phenotypes. 
  33 
(A) Diagram of Pho85 and Cdc4 consensus sites in isr1 that comprise a 
phosphodegron. Six sites (T3, T4, S8, T85, T86, S92) are mutated to alanine in the 
ISR1-PD mutant. (B) An Isr1 phosphodegron mutant is stable. Cycloheximide-chase 
assay of Isr1-13xmyc in wildtype, pho85∆, or cells expressing the phosphodegron 
mutant of ISR1 from the endogenous locus (ISR1-PD). Cycloheximide was added for 
the indicated number of minutes. Levels of Isr1-13xMyc and PSTAIR (loading control) 
are shown. (C) An Isr1 phosphodegron mutant is resistant to calcofluor white (CFW). 
Strains of the indicated genotypes were diluted onto YPD with or without 40 µg/ml CFW. 
(D) An Isr1 phosphodegron mutant is sensitive to tunicamycin. Experiment was 
performed as in C, except strains were spotted on YPD with or without 0.25 µg/ml 
tunicamycin. (E) Diploid strains of the indicated genotypes were diluted onto YPD with 
or without 0.25 µg/ml tunicamycin.  
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Fig 1.S1. Isr1 lethality is not rescued by osmotic stabilizers or other carbon 
sources. 
(A) Lethality of GAL-2µ ISR1 is not rescued by sorbitol. Cells of the indicated genotypes 
expressing EV or GAL- 2µ ISR1 were diluted onto YPD or YPGal + 10% sorbitol. (B) 
Lethality from GAL- 2µ ISR1 overexpression is not rescued by alternative carbon 
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sources. Wildtype cells were transformed with EV, GAL- 2µ ISR1 or GAL- 2µ isr1-
D280A and spotted onto CSM containing 2% glucose, galactose or the indicated carbon 
source. (C) Experiment performed as in B, but with 3% glycerol.  
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Fig 1.S2. Isr1 does not affect Gfa1 protein levels  
(A). 2µ ISR1 does not affect Gfa1 protein levels at any cell cycle stage. Cells were 
inoculated in CSM-URA and arrested in G1, S, and M phase with alpha factor, HU or 
nocodazole respectively. Note that Gfa1 was upregulated in response to alpha factor, 
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as expected. (B) GAL- 2µ ISR1 does not alter Gfa1 protein levels. Cells were grown 
overnight in CSM-URA raffinose and inoculated in CSM-URA galactose for 4 hours. (C) 
Cells of the indicated genotypes were transformed with EV or 2µ ISR1 and serial diluted 
on YPD with or without 30 µg/ml calcofluor white. (D) Diploids of the indicated 
genotypes were transformed with EV or 2µ ISR1 and spotted on YPD with or without 
0.25 µg/ml tunicamycin. 
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Fig 1.S3. Isr1 is partially stabilized in non-fermentable carbon sources  
(A) Isr1 is partially stabilized by glycerol/ethanol, but not galactose. Cycloheximide-
chase assay of Isr1-13xmyc grown in YM-1 containing 2% dextrose, 2% galactose or 
2% glycerol/1% ethanol. Cells were grown overnight in the indicated carbon source, 
inoculated in fresh media, and cycloheximide was added at 0.5 OD/ml for the indicated 
number of minutes. For the no glucose condition, cells were grown in YM-1 with 
dextrose, washed twice in media without a carbon source, and suspended in media with 
no carbon source at the same time as adding cycloheximide.   
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Fig 1.S4. Mutation of an Isr1 phosphodegron confers resistance to Congo Red   
(A) An Isr1 phosphodegron mutant is resistant to Congo Red. Strains of the indicated 
genotypes were diluted onto YPD in the presence or absence of 150 µg/ml Congo Red. 
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Fig 1.S5. PRR1 is not downstream of ISR1  
(A) prr1∆ cells expressing EV or Gal- 2µ ISR1 were serial diluted onto YPD or YPGal.  
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GTGATGTATGGGTCTATCTTATTGTTTATTTTGACTAGCATTGAATAAACAAAAAGC
GCTGCTAATAGATTCTTGCCTTTATATAACGGGGATCTAACCTCATCAACAGCAAAA
ATCGTCTTAAAACACATCTCAAAGACTAGTTCTCAAACGTCACGCTATGAACgctgCA
CCTCCTgccgCACCCGTCACCAGGGTTTCTGATGGTTCCTTTCCATCCATAAGTAAC
AATAGTAAGGGTTTTGCTTATCGCCAACCGCAAAAACATAAAAGTAACTTCGCATAT
TCACATCTGGTATCTCCTGTAGAGGAGCCGACAGCTAAATTCAGTGAGGCATTCCA
GACAGATTATTCTAGTAAGGCGCCCGTTGCTACCTCGGAGGCGCACCTAAAGAAC
GATTTAGACGTATTGTTCgCTgCCCCCCGGTTTTACgCTCCGGAGAATTTGGCTTTA
ATGTTCCGTCTTTCTAATACAGTTTCTTCCCTAGAATTTCTGGATGAGTTTTTGATGG
GCATATTACTTGCTCCAGAGATGGATTTTTTGTCAAATCCAAGTTATTCTCTTCCGT
CTAACAAATTAGTGGGACAGGGAAGTTATTCATATGTGTACCCTATATCATCAAGTG
CTTCATCAAGATGTAACAACGATTCAGGGGTTGTTTTAAAGTTTGCCAAATCACAGC
ATAAAAGCAAGGTGATTTTACAGGAAGCTTTGACGCTAGCATATCTCCAGTACATG
AGTCCTTCAAC 
Fig 1.S6. ISR1 Phosphodegron mutant sequence  
Double-stranded DNA sequence used to generate ISR1 phosphodegron mutant. Blue 
sequence is the end of the Isr1 promoter. Lowercase red base pairs indicate mutated 
residues. 
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Table 1.S1. Strains used in this study 
Strain Name Genotype Fig 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0  
EBA142 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
isr1Δ::KanMX 
2A 
EBA211 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
isr1Δ::HygMX 
2A, 3C, 
3D, 4B, 
4C, 6C, 
6D, S4 
EBA206 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
Pkc1-3xFlag::KanMX 
1C 
EBA183 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
ISR1-13xmyc::NAT 
6C, 6D, 
S4 
EBA185 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
ISR1-PD13xmyc::NAT 
6C, 6D, 
6E, S4A 
EBA176 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
isr1D280A::NAT 
6C, 6D, 
S4 
EBA151 MATα his3Δ1 ura3Δ0 leu2Δ0 lys2Δ0 
chs3Δ::KanMX 
2B,6C, 
6D, S4 
EBA160 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
GFA1-TAP-His3MX 
S2 
EBA329 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
GFA1-3A::HygMX 
4D, 4E, 
S2 
EBA330 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
GFA1-3A::HygMX 
4D, 4E, 
S2 
EBA326 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1/GFA1-3A::HygMX 
4F, S2 
EBA327 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1/GFA1-3A::HygMX 
4F, S2 
EBA114 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 
2E, 4F, 
6E, S2 
EBA268 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 ISR1/ISR1-PD::NAT 
6E 
EBA273 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1/gfa1∆::KanMX 
2E, 6E, 
S2 
EBA269 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1/gfa1∆::KanMX 
ISR1/ISR1-PD::NAT 
6E 
EBA368 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ S2 
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Strain Name Genotype Fig 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1-3A/GFA1-3A::HygMX 
EBA369 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GFA1-3A/GFA1-3A::HygMX 
S2 
EBA315 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GNA1/gna1∆::KANMX 
ISR1/ISR1-PD::NAT 
6E 
EBA316 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GNA1/gna1∆::∆::KANMX 
2E, 6E 
EBA302 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 GLN1/gln1∆::KANMX 
ISR1/ISR1-PD::NAT 
6E 
EBA319 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 PCM1/pcm1∆::KANMX 
2E, 6E 
EBA328 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 PCM1/pcm1∆::KANMX 
ISR1/ISR1-PD::NAT 
6E 
EBA304 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 QRi1/qri1∆::KANMX 
2E, 6E 
EBA303 MATa/MATα his3Δ1/ his3Δ1 ura3Δ0/ 
ura3Δ0 leu2Δ0/ leu2Δ0 MET15/met15Δ0 
LYS2/lys2∆0 QRi1/qri1∆∆::KANMX 
ISR1/ISR1-PD::NAT 
6E 
EBA135 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 Isr1-
13xmyc::URA3 
5A-E, 
6B, S3 
EBA153 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
pho85∆::KANMX Isr1-13xmyc::URA3 
5C, 6B 
EBA332 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
cdc4-1::HYGMX Isr1-13xmyc::URA3 
5B 
EBA158 MATα his3Δ1 ura3Δ0 leu2Δ0 lys2∆0 cdc53-
1 Isr1-13xmyc::URA3 
5B 
EBA331 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
pcl1∆::KANMX Isr1-13xmyc::URA3 
5C 
EBA174 MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
3xHA-Isr1∆93::NATMX 
6D 
knockout collection MATa his3Δ1 ura3Δ0 leu2Δ0 met15Δ0 
YFGΔ::KANMX 
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Table 1.S2. Plasmids used in this study 
Plasmid Name Description Fig/Use 
EBP294 Prs426 NAT (EV) 1A, 2B, 3B, 
3C, 3D, 4D, 
4E, S1, S2, 
S5 
 
EBP187 2µ ISR1 1B, 2B, 3C, 
4E, S2 
 
EBP290 2µ ISR1 isr1-D280A 2B, 3C 
 
EBP211 Gal- 2µ ISR1 1, 2C, 2E, 
3B, 3D, 4A, 
4B, 4C, 
4D,4F, S1, 
S2, S5 
 
EBP210 Gal- 2µ isr1-D280A 1A, 2C, 3B, 
3D, 4A, S1, 
S2  
 
EBP215 prs426NAT + GAL1-ISR13xFlag, GFA1pr-
GFA1 
4A 
EBP216 prs426NAT + GAL1-isr1D280A-3xFlag, 
GFA1pr-GFA1 
4A 
EBP211 prs426NAT + GAL1-ISR1-3xFlag, QRI1pr-
QRI1 
4A 
EBP212 prs426NAT + GAL1-isr1D280A-3xFlag, 
QRI1pr-QRI1 
4A 
EBP168 prs402NAT + ISR1pr-ISR1-13xMyc Construction 
of ISR1 
integration 
(wildtype) 
 
EBP181 prs402NAT + ISR1pr-ISR1PD-13xMyc Construction 
of ISR1-PD 
integration 
 
EBP172 prs402NAT + ISR1pr-isr1D280A Construction 
of isr1-
D280A 
integration 
 
EBP220 p3xFlagHYGMX + GFA1 Construction 
of GFA1 
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Plasmid Name Description Fig/Use 
integration 
(WT) 
 
EBP223 p3xFlagHYGMX + GFA1-
S332AT334AS336A 
Construction 
of GFA1-3A 
integration 
 
MS197 Prs306 + ISR1-13xMyc Construction 
of ISR1-
13xmyc 
tagged 
strains 
 
PYMN-20  PYMN-20 (66) Construction 
of HA-
ISR1∆93 
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Materials and Methods 
Strains and Plasmids 
Strains and plasmids used in this study are listed in Tables S2 and S3, respectively. All 
yeast strains in this study are in the S288C background. Unless otherwise noted, single 
gene deletions are from the Mat a deletion collection (Open Biosystems) and TAP-
tagged strains were a gift from Erin O’Shea and Jonathan Weismann. Cloning of 
constructs and transformations were done using standard techniques. Diploid 
heterozygous deletions were made by transformation of a KanMX cassette with 
homology to the promoter and 3’ UTR of the gene of interest into a wild type diploid or 
heterozygous ISR1-PD diploid strain. The ISR1-PD and GFA1-3A strains were 
constructed by gene replacement: point mutants were synthesized on a plasmid 
containing a nourseothricin (NAT) (ISR1) or HygMX (GFA1) selection marker (Table 
1.S2, Fig 1.S6). A PCR fragment was generated with homology to the endogenous 
promoter at the 5’ end and the MX cassette at the 3’ end. This PCR fragment was 
transformed into the deletion strain to replace the gene deletion previously marked by 
HygMX (ISR1) or KanMX (GFA1). Integrations were screened by marker loss/gain and 
then verified by PCR. In the case of GFA1, GFA1-3A was first generated in a 
GFA1/gfa1∆ diploid and haploid mutants were isolated by tetrad analysis.  
 
Yeast Cell Culture 
Selective media lacking specific amino acids or nucleobases was made using Complete 
Supplement Mixture (CSM) from Sunrise Sciences, supplemented with yeast nitrogen 
base and 2% dextrose. Unless otherwise noted, cells were cultured at 30°C on YM-1 
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media supplemented with 2% dextrose or CSM-URA to maintain plasmid selection. 100 
μg/ml NAT was added to maintain plasmids when strains were grown in YM-1. 
Expression from the GAL1 promoter was induced with 2% (wt/vol) galactose for 4 
hours. For experiments with temperature-sensitive strains, cells were maintained at 23 
°C and shifted to 37°C for 30 minutes before initiating the experiment. Low phosphate 
media was made as with CSM, but using YNB lacking amino acids and phosphate 
(Formedium CYN0803) and supplemented with 0.55g KCl/liter. To measure Isr1 protein 
levels in low phosphate, cells were washed several times in low-phosphate media and 
resuspended in low-phosphate media for 60 minutes. 
 
Western Blotting 
From cultures in midlog phase, cell pellets of equivalent optical densities were collected, 
washed with 1 mL 4°C H2O, and frozen on dry ice. Standard TCA precipitations were 
preformed to extract proteins. Samples were resuspended in SDS-PAGE sample buffer, 
boiled for 5 min, and cell lysates were analyzed by SDS-PAGE using 4–20% gradient 
Tis-HCl gels (BioRad, #3450034). Proteins were transferred onto 0.2-μm nitrocellulose 
membrane.  Western blots were performed with low-salt PBS with Tween-20 (PBS-T) 
(15 mM NaCl, 1.3 mM NaH2PO4, 5.4 mM Na2HPO4, 0.05% Tween-20). Primary 
antibody incubations were performed in 5% (wt/vol) nonfat dry milk and low-salt PBS-T. 
Antibodies were used as follows: α-Rad53 (Abcam ab104232); α-Flag (Sigma-Aldrich, 
F3165); α-Myc (BioLegend, #626802), α-PSTAIR (Sigma-Aldrich P7962), α-Pds1 
(generous gifts from Adam Rudner), α-TAP (Thermo-Scientific CAB1001). Western 
blots were visualized by LiCor Odyssey Imaging System. 
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Cell Cycle Arrest 
Cells were grown overnight in YM-1 and inoculated to OD600 = 0.2 and grown at 30°C 
for 45 minutes. For arrest in G1, 15 μg/mL alpha factor was added. After 90 minutes, an 
additional 10 μg/mL alpha factor was added. Cells were harvested after 2.5 hours. For 
arrest in S and M phase respectively, 200 mM HU or 15 μg /ml nocadozole was added 
and cells were harvested after 2 hours. Arrest was confirmed by microscopic analysis 
and equivalent ODs were processed for western blots as described above. 
 
Cycloheximide-Chase Assays 
Cells were grown as for western blotting to midlog phase. Cycloheximide was added to 
cultures for a final concentration of 50 µg/mL after collection at the t = 0 time point. 
Equivalent ODs were collected for each time point and were processed for western 
blots as described above. For cdc53-1 and cdc4-1 experiments, cells (including wild 
type control) were shifted to 37 °C for 30 minutes before addition of cycloheximide. For 
alternative carbon sources, cells were grown overnight in YM-1 supplemented with 2% 
dextrose, 2% galactose or 2% glycerol/1% ethanol, inoculated at 0.2 OD, and grown to 
mid-log phase before addition of cycloheximide. 
 
Mass Spectrometry  
Cell lysis and sample preparation. Cells were grown overnight in YM-1 supplemented 
with 2% raffinose and 100 μg/ml NAT and then inoculated at 0.3 OD. After 1 hour, 40% 
galactose was added to a final concentration of 2% galactose and cells were grown for 
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an additional 3 hours to OD ~0.8. 40 OD of cells were washed 2x with water and flash 
frozen in liquid nitrogen. Cells pellets were combined and lysed in a denaturing urea 
buffer (8 M urea, 0.1 M ammonium bicarbonate, pH 8, 150 mM NaCl, 1 Roche mini 
protease inhibitor tablet without EDTA/10 ml, ½ Roche phosSTOP tablet/10 ml) using 
14 × 1.5 min bursts on a BioSpec mini bead-beater at room temperature. 2 ml screw-
cap tubes used for lysis were pierced with an 18-gauge needle and spun in a swinging 
bucket centrifuge for 30 s at 1000 × g to collect extract. Extract was rotated end-over-
end for 30 min at room temperature before clarification via centrifugation at 17,000 
× g for 7 min followed by a second centrifugation at 17,000 × g for 2 min, both at room 
temperature. Extracts were quantitated using a BCA protein quantification kit (Pierce). 
1 M TCEP (Sigma C4706–2) was added to final concentration of 4 mM to 1 mg of protein 
and incubated for 30 min at room temperature. 0.5 M iodoacetamide (Sigma L1149–5G, 
prepared fresh in water) was added to a final concentration of 10 mM and incubated in 
the dark for 30 min. To quench excess iodoacetamide, 0.5 M DTT was added to a final 
concentration of 10 mM for another 30 min in the dark. Samples were diluted fourfold 
(to less than 2 M urea) with 0.1 M Tris, pH 8, and Lys-C/trypsin (Promega, Madison, WI, 
V5071, dissolved in 50 mM acetic acid) was added at a ratio of 200 ug trypsin to 1 mg 
total protein. Samples (1 ml total volume of diluted sample) were incubated for 20 
hours at room temperature with rotation. After digestion, TFA was added to a final 
concentration of 0.3–0.1% TFA, with pH of final solution ~2. 
Phosphopeptide enrichment by immobilized metal affinity chromatography. Iron 
nitrilotriacetic acid (NTA) resin were prepared in-house by stripping metal ions from 
nickel nitrilotriacetic acid agarose resin (Qiagen) with 100 mM 
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ethylenediaminetetraacetic (EDTA) acid, pH 8.0 three times. Resin was washed twice 
with water and 100 mM iron(III) chloride was applied three times. The iron-NTA resin 
was washed twice with water and once with 0.5% formic acid. Iron-NTA beads were 
resuspended in water to create a 25% resin slurry. 60 µl of Fe-NTA resin slurry was 
transferred to individual Silica C18 MicroSpin columns (The Nest Group) pre-
equilibrated with 100 µl of 80% ACN, 0.1% TFA on a vacuum manifold. Subsequent 
steps were performed with the Fe-NTA resin loaded on the Silica C18 columns. Peptide 
samples were mixed twice with the Fe-NTA resin and allowed to incubate for 2 minutes. 
The resin was rinsed four times with 200 µl of 80% ACN, 0.1% TFA. In order to 
equilibrate the chromatography columns, 200 µl of 0.5% formic acid was applied twice 
to the resin and columns. Peptides were eluted from the resin onto the C18 column by 
application of 200 µl of 500 mM potassium phosphate, pH 7.0. Peptides were washed 
twice with 200 µl of 0.5% formic acid. The C18 columns were removed from the vacuum 
manifold and eluted twice by centrifugation at 1000g with 60 µl of 50% ACN, 0.25% 
TFA. Peptides were dried with a centrifugal adaptor and stored at -20°C until analysis 
by liquid chromatograph and mass spectrometry. 
Proteomic data acquisition and analysis. Peptides were resuspened in 45 uL of 4% 
formic acid, 3% ACN, and 2uL was analyzed in on a Bruke timsTOF Pro mass 
spectrometry system equipped with an Bruker nanoElute high-pressure liquid 
chromatography system interfaced via a captiveSpray source. Samples were directly 
injected on a C18 reverse phase column (25 cm x 75 µm packed with ReprosilPur C18 
AQ 1.9 um particles). Peptides were separated by an organic gradient from 2 to 28% 
ACN at 400nl/min over the course of a 120 acquisition. Each sample was injected twice, 
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once with data-dependent PASEF acquisition to build a spectral library, and one via a 
diaPASEF acquisition for quantitative analysis. The mass spectrometry data files (raw 
and search results) have been deposited to the Chorus project ID 1643 
(www.chorusproject.org).  All data-dependent PASEF files [63] were search against the 
Saccharomyces cerevisiae proteome database (Downloaded from the Saccharomyces 
Genome Database January 13, 2015). Peptide and protein identification searches were 
performed with the Spectronaut Pulsar software (www.spectronaut.org) to generate a 
spectral library of detected phosphorylated peptides with a 1% false-discovery rate at 
the peptide and protein level.  Spectronaut was further used with the default settings to 
analyzed the diaPASEF data  [64] and extract quantitative regulation of detected 
phosphorylation sites.  Label-free quantification and statistical testing of phosphorylation 
sites was performed using the artMS R-package (version 1.3.7) 
(https://github.com/biodavidjm/artMS), and the MSstats statistical R-package (version 
3.16.0) [65]. Instant Clue [66] was used for figure generation of proteomics data. 
 
Spot Tests 
Yeast strains were inoculated into 3-5 ml YM-1 or CSM-URA + 2% dextrose grown 
overnight with aeration at 30°. Fivefold dilution series were set up in 96-well plates, and 
3-5 μl aliquots of the dilution series were transferred to YPD, YPGAL or CSM plates. 
Drug concentrations and alternative carbon sources are specified in individual figures. 
In experiments utilizing plasmids overexpressing ISR1, plates also contained 100 µg/ml 
NAT to maintain plasmid selection. Plates were incubated 2-3 days at 30° until colonies 
formed and then were photographed.   
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